Diaceutics (LON:DXRX) Earns “Buy” Rating from Canaccord Genuity Group

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a research note issued to investors on Wednesday,Digital Look reports. They currently have a GBX 215 price objective on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 63.87% from the stock’s previous close.

Diaceutics Stock Performance

Shares of DXRX traded up GBX 4.70 on Wednesday, reaching GBX 131.20. 1,928,193 shares of the stock traded hands, compared to its average volume of 182,702. Diaceutics has a 12 month low of GBX 125 and a 12 month high of GBX 180. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92. The stock’s 50-day moving average price is GBX 143.48 and its 200-day moving average price is GBX 153.46. The firm has a market cap of £111.03 million, a price-to-earnings ratio of 1,192.73 and a beta of 0.89.

Diaceutics (LON:DXRX) last announced its quarterly earnings results on Tuesday, May 26th. The company reported GBX 11 EPS for the quarter. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%. The firm had revenue of GBX 3,844 million during the quarter. Equities analysts forecast that Diaceutics will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.